Skip to content
1887

Microbiology Society logo Microbiology

Volume 171, Issue 6

Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder Open Access

Abstract

Despite being one of the most common and debilitating mood disorders, bipolar disorder is often misdiagnosed and undertreated. Its pathogenesis is complex, with significant patient variability and inconsistent treatment effectiveness. The brain-gut-microbiota axis plays a critical role in bipolar disorder by modulating neurotransmitter secretion, gut peptides and systemic inflammation. However, the mechanisms by which psychotropic treatments influence gut microbiota composition and their implications for clinical outcomes remain poorly understood. This systematic review evaluated the impact of psychotropic drugs on gut microbiota and their potential role in bipolar disorder treatment outcomes. A comprehensive search across Ovid MEDLINE, Embase, APA PsycINFO, Scopus and PubMed yielded 314 articles, of which 12 met the inclusion criteria (last search: 13 August 2024). The studies included were those on adults with bipolar disorder type I or II receiving psychopharmacological treatments; those with group comparisons (e.g. healthy controls vs. medicated vs. non-medicated) investigating gut microbiome changes; and no restrictions applied to psychotic features, comorbid anxiety or prior treatment responses. Exclusions involved individual case reports, incomplete conference submissions or early terminated studies lacking efficacy analysis. Cochrane ROBINS-I V2 tool was used to measure the risk of bias, and the GRADE approach was utilized to rate the certainty of evidence in included studies. Two authors independently extracted data into Excel spreadsheets, categorizing demographic and clinical characteristics, describing microbiome analytic methods and summarizing findings on gut microbiome changes post-treatment. Given the high variability in methods and outcome measures across studies, all details were reported without data conversion. Data synthesis reveals that psychotropic treatments, including quetiapine and lithium, influence gut microbiota by increasing the abundance of beneficial bacteria supporting gut health and pathogenic bacteria linked to metabolic dysfunction. Notably, female patients exhibited more significant changes in microbial diversity following psychotropic treatment. Additionally, patients treated with psychotropics showed an increased prevalence of gut bacteria associated with multidrug antibiotic resistance. In bipolar patients treated with quetiapine, responders – those experiencing improved depressive symptom scores – displayed distinct gut microbiome profiles more closely resembling those of healthy individuals compared with non-responders. Responders also exhibited neural connectivity patterns similar to healthy subjects. These findings underscore the complex dual impact of psychotropic medications on gut microbiota, with potential consequences for both gut and mental health. While the enrichment of beneficial bacteria may support gut health, the rise in antibiotic-resistant and metabolically disruptive bacteria is concerning. Study limitations include methodological heterogeneity, inclusions of other psychiatric disorders, a high risk of bias in some studies due to incomplete statistical analyses or insufficient control for confounding factors and potential duplication of study populations arising from overlapping authorship. Further research is essential to elucidate the functional consequences of these microbial shifts and their influence on treatment efficacy. Nevertheless, this review highlights the potential of utilizing gut microbiota profiles to inform personalized treatment strategies, optimize therapeutic outcomes and minimize side effects in bipolar disorder. This study was registered with Open Science Framework (https://doi.org/10.17605/OSF.IO/3GUZR).

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antipsychotics , bipolar disorder , gastrointestinal microbiota/microbiome , mood stabilizers and psychotropics
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.001568
2025-06-18
2025-07-08
Loading full text...

Full text loading...

/deliver/fulltext/micro/171/6/mic001568.html?itemId=/content/journal/micro/10.1099/mic.0.001568&mimeType=html&fmt=ahah

References

  1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134:577–594 [View Article] [PubMed]
     [Google Scholar]
  2. Schmidt C, Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 2005; 51:127–145 [PubMed]
     [Google Scholar]
  3. Lukiw WJ. Gastrointestinal (GI) tract microbiome-derived neurotoxins—potent neuro-inflammatory signals from the GI tract via the systemic circulation into the brain. Front Cell Infect Microbiol 2020; 10:22 [View Article]
     [Google Scholar]
  4. King CH, Desai H, Sylvetsky AC, LoTempio J, Ayanyan S et al. Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS One 2019; 14:e0206484 [View Article] [PubMed]
     [Google Scholar]
  5. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L et al. Diversity of the human intestinal microbial flora. Science 2005; 308:1635–1638 [View Article] [PubMed]
     [Google Scholar]
  6. Davenport ER, Mizrahi-Man O, Michelini K, Barreiro LB, Ober C et al. Seasonal variation in human gut microbiome composition. PLoS One 2014; 9:e90731 [View Article] [PubMed]
     [Google Scholar]
  7. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci 2006; 8:383–395 [View Article] [PubMed]
     [Google Scholar]
  8. Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M et al. The hypothalamic-pituitary-adrenal axis: development, programming actions of hormones, and maternal-fetal interactions. Front behav neurosci [Internet]; 2021 https://www.frontiersin.org/articles/10.3389/fnbeh.2020.601939 accessed 3 July 2023
  9. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res 2018; 1693:128–133 [View Article] [PubMed]
     [Google Scholar]
  10. Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients 2021; 13:2099 [View Article]
     [Google Scholar]
  11. Bhatia NY, Jalgaonkar MP, Hargude AB, Sherje AP, Oza MJ et al. Gut-brain axis and neurological disorders-how microbiomes affect our mental health. CNS Neurol Disord Drug Targets 2023; 22:1008–1030 [View Article] [PubMed]
     [Google Scholar]
  12. Park AJ, Collins J, Blennerhassett PA, Ghia JE, Verdu EF et al. Altered colonic function and microbiota profile in a mouse model of chronic depression. Neurogastroenterol Motil 2013; 25:733–e575 [View Article] [PubMed]
     [Google Scholar]
  13. Tillmann S, Abildgaard A, Winther G, Wegener G. Altered fecal microbiota composition in the flinders sensitive line rat model of depression. Psychopharmacology 2019; 236:1445–1457 [View Article] [PubMed]
     [Google Scholar]
  14. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015; 48:186–194 [View Article] [PubMed]
     [Google Scholar]
  15. Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA et al. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res 2017; 87:23–29 [View Article] [PubMed]
     [Google Scholar]
  16. Schwarz E, Maukonen J, Hyytiäinen T, Kieseppä T, Orešič M et al. Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophr Res 2018; 192:398–403 [View Article] [PubMed]
     [Google Scholar]
  17. Liu YZ, Wang YX, Jiang CL. Inflammation: the common pathway of stress-related diseases. Front Hum Neurosci 2017; 11:316 [View Article] [PubMed]
     [Google Scholar]
  18. Chrobak AA, Nowakowski J, Dudek D. Interactions between the gut microbiome and the central nervous system and their role in schizophrenia, bipolar disorder and depression. Arch Psych Psych 2016; 18:5–11 [View Article]
     [Google Scholar]
  19. Maqsood R, Stone TW. The Gut-Brain axis, BDNF, NMDA and CNS disorders. Neurochem Res 2016; 41:2819–2835 [View Article] [PubMed]
     [Google Scholar]
  20. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001; 21:6348–6361 [View Article]
     [Google Scholar]
  21. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657–1664 [View Article] [PubMed]
     [Google Scholar]
  22. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD et al. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16:2352–2364 [View Article]
     [Google Scholar]
  23. Bischoff SC, Mailer R, Pabst O, Weier G, Sedlik W et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J Physiol Gastrointest Liver Physiol 2009; 296:G685–95 [View Article] [PubMed]
     [Google Scholar]
  24. Haub S, Ritze Y, Bergheim I, Pabst O, Gershon MD et al. Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter. Neurogastroenterol Motil 2010; 22:826–834 [View Article] [PubMed]
     [Google Scholar]
  25. Yamada T, Inui A, Hayashi N, Fujimura M, Fujimiya M. Serotonin stimulates endotoxin translocation via 5-HT3 receptors in the rat ileum. Am J Physiol Gastrointest Liver Physiol 2003; 284:G782–8 [View Article] [PubMed]
     [Google Scholar]
  26. Hemmings SMJ, Malan-Müller S, van den Heuvel LL, Demmitt BA, Stanislawski MA et al. The microbiome in posttraumatic stress disorder and trauma-exposed controls: an exploratory study. Psychosom Med 2017; 79:936–946 [View Article] [PubMed]
     [Google Scholar]
  27. Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N et al. A step ahead: exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar Disord 2019; 21:40–49 [View Article] [PubMed]
     [Google Scholar]
  28. Liu L, Wang H, Chen X, Zhang Y, Zhang H et al. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine 2023; 90:104527 [View Article] [PubMed]
     [Google Scholar]
  29. Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM et al. Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis. JAMA Psychiatry 2021; 78:1343–1354 [View Article] [PubMed]
     [Google Scholar]
  30. Afroz KF, Manchia M. Gut microbiome and psychiatric disorders. BMC Psychiatry 2023; 23:488 [View Article] [PubMed]
     [Google Scholar]
  31. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry 2016; 3:171–178 [View Article] [PubMed]
     [Google Scholar]
  32. Merikangas KR, Jin R, He J-P, Kessler RC, Lee S et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68:241–251 [View Article] [PubMed]
     [Google Scholar]
  33. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 2020; 396:1204–1222 [View Article]
     [Google Scholar]
  34. Oldis M, Murray G, Macneil CA, Hasty MK, Daglas R et al. Trajectory and predictors of quality of life in first episode psychotic mania. J Affect Disord 2016; 195:148–155 [View Article] [PubMed]
     [Google Scholar]
  35. Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ et al. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry 2006; 67:1209–1218 [View Article] [PubMed]
     [Google Scholar]
  36. Macneil CA, Hasty MK, Berk M, Henry L, Evans M et al. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry 2011; 5:100–107 [View Article] [PubMed]
     [Google Scholar]
  37. Marwaha S, Durrani A, Singh S. Employment outcomes in people with bipolar disorder: a systematic review. Acta Psychiatr Scand 2013; 128:179–193 [View Article] [PubMed]
     [Google Scholar]
  38. Preuss UW, Schaefer M, Born C, Grunze H. Bipolar disorder and comorbid use of illicit substances. Medicina 2021; 57:1256 [View Article]
     [Google Scholar]
  39. Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T et al. Bipolar disorders. Nat Rev Dis Primers 2018; 4:1–16 [View Article]
     [Google Scholar]
  40. Smith DJ, Whitham EA, Ghaemi SN. Chapter 15 - Bipolar disorder. In Aminoff MJ, Boller F, Swaab DF. eds Handbook of Clinical Neurology [Internet] vol 106 Elsevier; 2012 pp 251–263 [View Article]
     [Google Scholar]
  41. Library DSM. Diagnostic and statistical manual of mental disorders. n.d https://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787 accessed 3 March 2023
  42. Assocation AP. Bipolar and Related Disorders. In Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-5-TR), 5th. edn
    [Google Scholar]
  43. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ et al. Canadian network for mood and anxiety treatments (canmat) and international society for bipolar disorders (isbd) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97–170 [View Article] [PubMed]
     [Google Scholar]
  44. Butler M, Urosevic S, Desai P. Treatment for bipolar disorder in adults: a systematic review [Internet]. Rockville (MD); 2023 http://www.ncbi.nlm.nih.gov/books/NBK532183/ accessed 12 March 2023
  45. Joshi A, Bow A, Agius M. Pharmacological therapies in bipolar disorder: a review of current treatment options. Psychiatr Danub 2019; 31:595–603 [PubMed]
     [Google Scholar]
  46. Butler M, Urosevic S, Desai P. Drug Treatments for Acute Mania. In Treatment for Bipolar Disorder in Adults: A Systematic Review Agency for Healthcare Research and Quality (US); 2018 https://www.ncbi.nlm.nih.gov/books/NBK532191/ accessed 2 July 2023
     [Google Scholar]
  47. Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord 2018; 6:25 [View Article] [PubMed]
     [Google Scholar]
  48. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? a proof of concept study. J Affect Disord 2006; 92:205–214 [View Article] [PubMed]
     [Google Scholar]
  49. Zhang Y, Yang H, Yang S, Liang W, Dai P et al. Antidepressants for bipolar disorder: a meta-analysis of randomized, double-blind, controlled trials. Neural Regen Res 2013; 8:2962–2974
     [Google Scholar]
  50. Jefsen OH, Rohde C, Østergaard SD. Revisiting the association between treatment with antidepressants and mania: a nationwide within-individual study of 3554 patients with bipolar disorder. Bipolar Disord 2023; 25:583–591 [View Article] [PubMed]
     [Google Scholar]
  51. Cosgrove VE, Kelsoe JR, Suppes T. Toward a valid animal model of bipolar disorder: how the research domain criteria help bridge the clinical-basic science divide. Biological Psychiatry 2016; 79:62–70 [View Article]
     [Google Scholar]
  52. Scolnick EM. The path to new therapies for schizophrenia and bipolar illness. FASEB J 2017; 31:1254–1259 [View Article]
     [Google Scholar]
  53. Kim Y, Santos R, Gage FH, Marchetto MC. Molecular mechanisms of bipolar disorder: progress made and future challenges. Front Cell Neurosci 20172 July 2023 11:30 [View Article] [PubMed]
     [Google Scholar]
  54. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK et al. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry 2010; 71:1488–1501 [View Article] [PubMed]
     [Google Scholar]
  55. Amann B, Radua J, König B, Simhandl C. Relapse rates and risk factors of bipolar disorder: conclusions of a naturalistic 4 year follow-up study. European Psychiatry 2015; 30:181 [View Article]
     [Google Scholar]
  56. Kessing LV, Andersen PK, Vinberg M. Risk of recurrence after a single manic or mixed episode - a systematic review and meta-analysis. Bipolar Disord 2018; 20:9–17 [View Article] [PubMed]
     [Google Scholar]
  57. Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. Nat Med 2016; 22:1248–1255 [View Article] [PubMed]
     [Google Scholar]
  58. Wang YX, Deng M. Medical imaging in new drug clinical development. J Thorac Dis 2010; 2:245–252 [View Article] [PubMed]
     [Google Scholar]
  59. Masdeu JC. Neuroimaging in psychiatric disorders. Neurotherapeutics 2011; 8:93–102 [View Article]
     [Google Scholar]
  60. Etkin A, Powell J, Savitz AJ. Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective. Neuropsychopharmacology 2024; 50:258–268 [View Article] [PubMed]
     [Google Scholar]
  61. Yatham LN, Liddle PF, Lam RW, Shiah I-S, Lane C et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry 2002; 159:1718–1723 [View Article] [PubMed]
     [Google Scholar]
  62. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48:813–829 [View Article] [PubMed]
     [Google Scholar]
  63. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999; 46:1375–1387 [View Article] [PubMed]
     [Google Scholar]
  64. Ongür D, Lundy M, Greenhouse I, Shinn AK, Menon V et al. Default mode network abnormalities in bipolar disorder and schizophrenia. Psychiatry Res 2010; 183:59–68 [View Article] [PubMed]
     [Google Scholar]
  65. Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry 2014; 171:829–843 [View Article] [PubMed]
     [Google Scholar]
  66. Zovetti N, Rossetti MG, Perlini C, Maggioni E, Bontempi P et al. Default mode network activity in bipolar disorder. Epidemiol Psychiatr Sci 2020; 29:e166 [View Article] [PubMed]
     [Google Scholar]
  67. Strakowski SM, Eliassen JC, Lamy M, Cerullo MA, Allendorfer JB et al. Functional magnetic resonance imaging brain activation in bipolar mania: evidence for disruption of the ventrolateral prefrontal-amygdala emotional pathway. Biol Psychiatry 2011; 69:381–388 [View Article] [PubMed]
     [Google Scholar]
  68. Yoon S, Kim TD, Kim J, Lyoo IK. Altered functional activity in bipolar disorder: a comprehensive review from a large-scale network perspective. Brain Behav 2021; 11:e01953 [View Article] [PubMed]
     [Google Scholar]
  69. Zhao L, Bo Q, Zhang Z, Li F, Zhou Y et al. Disrupted default mode network connectivity in bipolar disorder: a resting-state fMRI study. BMC Psychiatry 2024; 24:428 [View Article] [PubMed]
     [Google Scholar]
  70. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35:121–127 [View Article] [PubMed]
     [Google Scholar]
  71. Young AH, Hughes JH, Ashton CH. Brain 5-HT function in bipolar affective disorder. Acta Neuropsychiatr 2000; 12:91–95 [View Article] [PubMed]
     [Google Scholar]
  72. Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord 2001; 66:1–11 [View Article] [PubMed]
     [Google Scholar]
  73. Li H, Wang P, Zhou Y, Zhao F, Gao X et al. Correlation between intestinal microbiotal imbalance and 5-HT metabolism, immune inflammation in chronic unpredictable mild stress male rats. Genes Brain Behav 2022; 21:e12806 [View Article] [PubMed]
     [Google Scholar]
  74. Kwon YH, Wang H, Denou E, Ghia J-E, Rossi L et al. Modulation of gut microbiota composition by serotonin signaling influences intestinal immune response and susceptibility to colitis. Cell Mol Gastroenterol Hepatol 2019; 7:709–728 [View Article] [PubMed]
     [Google Scholar]
  75. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161:264–276 [View Article] [PubMed]
     [Google Scholar]
  76. Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J et al. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry 2016; 21:738–748 [View Article] [PubMed]
     [Google Scholar]
  77. Takahashi H, Yahata N, Koeda M, Takano A, Asai K et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fmri study. Neuroimage 2005; 27:991–1001 [View Article] [PubMed]
     [Google Scholar]
  78. Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav 2008; 13:383–395 [View Article] [PubMed]
     [Google Scholar]
  79. Hori Y, Iwaoki H, Mimura K, Nagai Y, Higuchi M et al. Effects of a 5-HT4 receptor antagonist in the caudate nucleus on the performance of macaques in a delayed reward task. Sci Rep 2024; 14:19619 [View Article] [PubMed]
     [Google Scholar]
  80. Lin P, Li D, Shi Y, Li Q, Guo X et al. Dysbiosis of the gut microbiota and kynurenine (Kyn) pathway activity as potential biomarkers in patients with major depressive disorder. Nutrients 2023; 15:1752 [View Article] [PubMed]
     [Google Scholar]
  81. Gao K, Mu C-L, Farzi A, Zhu W-Y. Tryptophan metabolism: a link between the gut microbiota and brain. Adv Nutr 2020; 11:709–723 [View Article] [PubMed]
     [Google Scholar]
  82. Więdłocha M, Marcinowicz P, Janoska-Jaździk M, Szulc A. Gut microbiota, kynurenine pathway and mental disorders – review. Prog Neuropsychopharmacol Biol Psychiatry 2021; 106:110145 [View Article] [PubMed]
     [Google Scholar]
  83. Buey B, Forcén A, Grasa L, Layunta E, Mesonero JE et al. Gut microbiota-derived short-chain fatty acids: novel regulators of intestinal serotonin transporter. Life 2023; 13:1085 [View Article] [PubMed]
     [Google Scholar]
  84. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156:84–96 [View Article] [PubMed]
     [Google Scholar]
  85. Liu P, Peng G, Zhang N, Wang B, Luo B. Crosstalk between the gut microbiota and the brain: an update on neuroimaging findings. Front Neurol 2019; 10:883 [View Article]
     [Google Scholar]
  86. Kao ACC, Spitzer S, Anthony DC, Lennox B, Burnet PWJ. Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. Transl Psychiatry 2018; 8:66 [View Article] [PubMed]
     [Google Scholar]
  87. Bahr SM, Weidemann BJ, Castro AN, Walsh JW, deLeon O et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2015; 2:1725–1734 [View Article]
     [Google Scholar]
  88. Davey KJ, Cotter PD, O’Sullivan O, Crispie F, Dinan TG et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry 2013; 3:e309 [View Article] [PubMed]
     [Google Scholar]
  89. Morgan AP, Crowley JJ, Nonneman RJ, Quackenbush CR, Miller CN et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One 2014; 9:e115225 [View Article] [PubMed]
     [Google Scholar]
  90. Cussotto S, Strain CR, Fouhy F, Strain RG, Peterson VL et al. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology 2019; 236:1671–1685 [View Article]
     [Google Scholar]
  91. Torrent C, Amann B, Sánchez-Moreno J, Colom F, Reinares M et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118:4–18 [View Article] [PubMed]
     [Google Scholar]
  92. Falony G, Vandeputte D, Caenepeel C, Vieira-Silva S, Daryoush T et al. The human microbiome in health and disease: hype or hope. Acta Clin Belg 2019; 74:53–64 [View Article] [PubMed]
     [Google Scholar]
  93. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555:623–628 [View Article] [PubMed]
     [Google Scholar]
  94. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis. World Psychiatry 2016; 15:166–174 [View Article]
     [Google Scholar]
  95. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. AJP 2013; 170:265–274 [View Article]
     [Google Scholar]
  96. McGuinness AJ, Davis JA, Dawson SL, Loughman A, Collier F et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry 2022; 27:1920–1935 [View Article] [PubMed]
     [Google Scholar]
  97. Ortega MA, Álvarez-Mon MA, García-Montero C, Fraile-Martínez Ó, Monserrat J et al. Microbiota-gut-brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities. Mol Psychiatry 2023; 28:2645–2673 [View Article] [PubMed]
     [Google Scholar]
  98. Sublette ME, Cheung S, Lieberman E, Hu S, Mann JJ et al. Bipolar disorder and the gut microbiome: a systematic review. Bipolar Disord 2021; 23:544–564 [View Article] [PubMed]
     [Google Scholar]
  99. Obi-Azuike C, Ebiai R, Gibson T, Hernandez A, Khan A et al. A systematic review on gut-brain axis aberrations in bipolar disorder and methods of balancing the gut microbiota. Brain Behav 2023; 13:e3037 [View Article] [PubMed]
     [Google Scholar]
  100. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097 [View Article] [PubMed]
     [Google Scholar]
  101. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology 2013; 230:291–298 [View Article] [PubMed]
     [Google Scholar]
  102. Boutron I, Page MJ, Higgins JP, Altman DG, Lundh A et al. Considering bias and conflicts of interest among the included studies. In Cochrane Handbook for Systematic Reviews of Interventions [Internet] John Wiley & Sons, Ltd; 2019 pp 177–204 [View Article]
     [Google Scholar]
  103. Lai J, Li A, Jiang J, Yuan X, Zhang P et al. Metagenomic analysis reveals gut bacterial signatures for diagnosis and treatment outcome prediction in bipolar depression. Psychiatry Res 2022; 307:114326 [View Article] [PubMed]
     [Google Scholar]
  104. Xi C, Li A, Lai J, Huang X, Zhang P et al. Brain-gut microbiota multimodal predictive model in patients with bipolar depression. J Affect Disord 2023; 323:140–152 [View Article] [PubMed]
     [Google Scholar]
  105. Coello K, Hansen TH, Sørensen N, Munkholm K, Kessing LV et al. Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Brain Behav Immun 2019; 75:112–118 [View Article] [PubMed]
     [Google Scholar]
  106. Jiang HY, Xu LL, Zhang X, Zhang Z, Ruan B. The microbiome in bipolar depression: a longitudinal study of one pair of monozygotic twins. Bipolar Disord 2019; 21:93–97 [PubMed]
     [Google Scholar]
  107. Gashaw M, Marame ZH, Abera M, Ali S. Assessment of gut bacteria profile and antibiotic resistance pattern among psychotropic drug users: comparative cross-sectional study. IDR 2021; Volume 14:1875–1881 [View Article]
     [Google Scholar]
  108. Ioannou M, Borkent J, Andreu-Sánchez S, Wu J, Fu J et al. Reproducible gut microbial signatures in bipolar and schizophrenia spectrum disorders: a metagenome-wide study. Brain Behav Immun 2024; 121:165–175 [View Article] [PubMed]
     [Google Scholar]
  109. Severance EG, Gressitt KL, Stallings CR, Origoni AE, Khushalani S et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013; 148:130–137 [View Article] [PubMed]
     [Google Scholar]
  110. Lu Q, Lai J, Lu H, Ng C, Huang T et al. Gut microbiota in bipolar depression and its relationship to brain function: an advanced exploration. Front Psychiatry 2019; 10:784 [View Article] [PubMed]
     [Google Scholar]
  111. Flowers SA, Baxter NT, Ward KM, Kraal AZ, McInnis MG et al. Effects of atypical antipsychotic treatment and resistant starch supplementation on gut microbiome composition in a cohort of patients with bipolar disorder or schizophrenia. Pharmacotherapy 2019; 39:161–170 [View Article] [PubMed]
     [Google Scholar]
  112. Hu S, Li A, Huang T, Lai J, Li J et al. Gut microbiota changes in patients with bipolar depression. Adv Sci 2019; 6:1900752 [View Article] [PubMed]
     [Google Scholar]
  113. Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL. Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 2017; 37:261–267 [View Article]
     [Google Scholar]
  114. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence [Internet]. n.d https://training.cochrane.org/handbook/current/chapter-14 accessed 17 January 2025
  115. Davey KJ, O’Mahony SM, Schellekens H, O’Sullivan O, Bienenstock J et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology 2012; 221:155–169 [View Article] [PubMed]
     [Google Scholar]
  116. Aichhorn W, Marksteiner J, Walch T, Zernig G, Hinterhuber H et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17:665–674 [View Article] [PubMed]
     [Google Scholar]
  117. Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender. Pharmacogenomics 2009; 10:1511–1526 [View Article] [PubMed]
     [Google Scholar]
  118. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341:1241214 [View Article] [PubMed]
     [Google Scholar]
  119. Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry 2015; 5:e652 [View Article] [PubMed]
     [Google Scholar]
  120. Dempsey E, Corr SC. Lactobacillus spp. for gastrointestinal health: current and future perspectives. Front Immunol 2022; 13:840245 [View Article] [PubMed]
     [Google Scholar]
  121. Rastogi S, Singh A. Gut microbiome and human health: exploring how the probiotic genus Lactobacillus modulate immune responses. Front Pharmacol 2022; 13:1042189 [View Article] [PubMed]
     [Google Scholar]
  122. Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes 2020; 12:1802866 [View Article]
     [Google Scholar]
  123. Moens F, De Vuyst L. Inulin-type fructan degradation capacity of clostridium cluster IV and XIVa butyrate-producing colon bacteria and their associated metabolic outcomes. Benef Microbes 2017; 8:473–490 [View Article] [PubMed]
     [Google Scholar]
  124. Kiu R, Hall LJ. An update on the human and animal enteric pathogen Clostridium perfringens. Emerg Microbes Infect 2018; 7:141 [View Article] [PubMed]
     [Google Scholar]
  125. Clegg S, Murphy CN. Epidemiology and Virulence of Klebsiella pneumoniae. Microbiol Spectr 2016; 4: [View Article] [PubMed]
     [Google Scholar]
  126. Wang G, Zhao G, Chao X, Xie L, Wang H. The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae. Int J Environ Res Public Health 2020; 17:6278 [View Article] [PubMed]
     [Google Scholar]
  127. Linscott AJ, Flamholtz RB, Shukla D, Song Y, Liu C et al. Fatal septicemia due to Clostridium hathewayi and Campylobacter hominis. Anaerobe 2005; 11:97–98 [View Article] [PubMed]
     [Google Scholar]
  128. Man SM, Kaakoush NO, Leach ST, Nahidi L, Lu HK et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J Infect Dis 2010; 202:1855–1865 [View Article] [PubMed]
     [Google Scholar]
  129. Candelli M, Franza L, Pignataro G, Ojetti V, Covino M et al. Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases. Int J Mol Sci 2021; 22:6242 [View Article] [PubMed]
     [Google Scholar]
  130. Huang S, Hu S, Liu S, Tang B, Liu Y et al. Lithium carbonate alleviates colon inflammation through modulating gut microbiota and treg cells in a GPR43-dependent manner. Pharmacol Res 2022; 175:105992 [View Article] [PubMed]
     [Google Scholar]
  131. Clarke SF, Murphy EF, O’Sullivan O, Ross RP, O’Toole PW et al. Targeting the microbiota to address diet-induced obesity: a time dependent challenge. PLoS One 2013; 8:e65790 [View Article] [PubMed]
     [Google Scholar]
  132. Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL et al. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev 2013; 71:790–801 [View Article] [PubMed]
     [Google Scholar]
  133. Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep 2015; 5:16643 [View Article] [PubMed]
     [Google Scholar]
  134. Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T et al. Bifidobacterium and Lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls. Front Psychiatry 2019; 9:730 [View Article] [PubMed]
     [Google Scholar]
  135. Huang R, Liu Y. Efficacy of bifidobacterium-related preparations on depression: the first meta-analysis. Front Psychiatry 202412 April 2025 15:1463848 [View Article] [PubMed]
     [Google Scholar]
  136. Li J, Wang J, Wang M, Zheng L, Cen Q et al. Bifidobacterium: a probiotic for the prevention and treatment of depression. Front Microbiol 2023; 14:1174800 [View Article]
     [Google Scholar]
  137. Tian P, O’Riordan KJ, Lee Y-K, Wang G, Zhao J et al. Towards a psychobiotic therapy for depression: Bifidobacterium breve CCFM1025 reverses chronic stress-induced depressive symptoms and gut microbial abnormalities in mice. Neurobiol Stress 2020; 12:100216 [View Article] [PubMed]
     [Google Scholar]
  138. Yang M, Cui X, Kong D, Huang X, Zhao G et al. The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2024 [View Article] [PubMed]
     [Google Scholar]
  139. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?. Therap Adv Gastroenterol 2013; 6:53–68 [View Article]
     [Google Scholar]
  140. Han Y, Guo X, Thanuphol P, Ji R, Zhu Z et al. Gut microbiota-mediated degradation of food-grade lambda-carrageenan by Bacteroides xylanisolvens and Its role in inflammation. J Agric Food Chem 2025; 73:4288–4298 [View Article] [PubMed]
     [Google Scholar]
  141. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun 2018; 9:3294 [View Article] [PubMed]
     [Google Scholar]
  142. Danzeisen JL, Calvert AJ, Noll SL, McComb B, Sherwood JS et al. Succession of the turkey gastrointestinal bacterial microbiome related to weight gain. PeerJ 2013; 1:e237 [View Article] [PubMed]
     [Google Scholar]
  143. Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: a randomized trial. Diabetes Care 2021; 44:1462–1471 [View Article] [PubMed]
     [Google Scholar]
  144. Elbere I, Silamikelis I, Dindune II, Kalnina I, Briviba M et al. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. PLoS One 2020; 15:e0241338 [View Article]
     [Google Scholar]
  145. Rosario D, Benfeitas R, Bidkhori G, Zhang C, Uhlen M et al. Understanding the representative gut microbiota dysbiosis in metformin-treated type 2 diabetes patients using genome-scale metabolic modeling. Front Physiol 2018; 9:775 [View Article] [PubMed]
     [Google Scholar]
  146. Conio B, Martino M, Magioncalda P, Escelsior A, Inglese M et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry 2020; 25:82–93 [View Article] [PubMed]
     [Google Scholar]
  147. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553–559 [View Article] [PubMed]
     [Google Scholar]
  148. Ramadan E, Basselin M, Rao JS, Chang L, Chen M et al. Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder. Int J Neuropsychopharmacol 2012; 15:931–943 [View Article] [PubMed]
     [Google Scholar]
  149. Willner K, Vasan S, Abdijadid S. Atypical Antipsychotic Agents. In StatPearls [Internet]. Treasure Island (FL) StatPearls Publishing; 2023 http://www.ncbi.nlm.nih.gov/books/NBK448156/ accessed 25 August 2023
     [Google Scholar]
  150. Grinchii D, Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. IJMS 2020; 21:9532 [View Article]
     [Google Scholar]
  151. Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Sig Transduct Target Ther [accessed December 2024] 2024 https://www.nature.com/articles/s41392-024-01743-1
     [Google Scholar]
  152. North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. WJG 2007; 13:2020 [View Article]
     [Google Scholar]
  153. Hui Poon S, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol 2015; 13:592–604 [View Article] [PubMed]
     [Google Scholar]
  154. Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep 2014; 16:431 [View Article] [PubMed]
     [Google Scholar]
  155. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 2014; 7:17–44 [View Article] [PubMed]
     [Google Scholar]
  156. Haggarty SJ, Karmacharya R, Perlis RH. Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry 2021; 26:168–185 [View Article] [PubMed]
     [Google Scholar]
  157. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63:349–352 [View Article] [PubMed]
     [Google Scholar]
  158. Angst J, Cassano G. The mood spectrum: improving the diagnosis of bipolar disorder. Bipolar Disord 2005; 7 Suppl 4:4–12 [View Article] [PubMed]
     [Google Scholar]
  159. Ghosh TS, Shanahan F, O’Toole PW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol 2022; 19:565–584 [View Article] [PubMed]
     [Google Scholar]
  160. Meng C, Feng S, Hao Z, Dong C, Liu H. Changes in gut microbiota composition with age and correlations with gut inflammation in rats. PLoS One 2022; 17:e0265430 [View Article]
     [Google Scholar]
  161. Keshavan MS, Morris DW, Sweeney JA, Pearlson G, Thaker G et al. A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: the schizo-bipolar scale. Schizophr Res 2011; 133:250–254 [View Article] [PubMed]
     [Google Scholar]
  162. Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and continuity of schizophrenia and bipolar disorder: relation to biomarkers. Curr Pharm Des 2020; 26:191–200 [View Article] [PubMed]
     [Google Scholar]
  163. Zbozinek TD, Rose RD, Wolitzky-Taylor KB, Sherbourne C, Sullivan G et al. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. Depress Anxiety 2012; 29:1065–1071 [View Article] [PubMed]
     [Google Scholar]
  164. Schulze TG, Akula N, Breuer R, Steele J, Nalls MA et al. Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder. World J Biol Psychiatry 2014; 15:200–208 [View Article] [PubMed]
     [Google Scholar]
  165. Pearlson GD. Phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. Annu Rev Clin Psychol 2015; 11:251–281 [View Article]
     [Google Scholar]
  166. Kempf L, Hussain N, Potash JB. Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: trouble at the borders. Int Rev Psychiatry 2005; 17:9–19 [View Article] [PubMed]
     [Google Scholar]
  167. Escamilla MA. Diagnosis and treatment of mood disorders that co-occur with schizophrenia. Psychiatr Serv 2001; 52:911–919 [View Article] [PubMed]
     [Google Scholar]
  168. Chen CK, Wu LSH, Huang MC, Kuo CJ, Cheng ATA. Antidepressant treatment and manic switch in bipolar I disorder: a clinical and molecular genetic study. J Pers Med 2022; 12:615 [View Article] [PubMed]
     [Google Scholar]
  169. Patel R, Reiss P, Shetty H, Broadbent M, Stewart R et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? a retrospective electronic case register cohort study. BMJ Open 2015; 5:e008341 [View Article] [PubMed]
     [Google Scholar]
  170. Barbuti M, Menculini G, Verdolini N, Pacchiarotti I, Kotzalidis GD et al. A systematic review of manic/hypomanic and depressive switches in patients with bipolar disorder in naturalistic settings: The role of antidepressant and antipsychotic drugs. European Neuropsychopharmacology 2023; 73:1–15 [View Article]
     [Google Scholar]
  171. Kamath S, Hunter A, Collins K, Wignall A, Joyce P. The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats. British J Pharmacology 2024; 181:4531–4545 [View Article]
     [Google Scholar]
  172. Lukić I, Getselter D, Ziv O, Oron O, Reuveni E et al. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior. Transl Psychiatry 2019; 9:133 [View Article] [PubMed]
     [Google Scholar]
  173. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146:1489–1499 [View Article] [PubMed]
     [Google Scholar]
  174. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53:685–693 [View Article] [PubMed]
     [Google Scholar]
  175. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480–484 [View Article] [PubMed]
     [Google Scholar]
  176. Zhang W, Qu W, Wang H, Yan H. Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress. Transl Psychiatry 2021; 11:131 [View Article] [PubMed]
     [Google Scholar]
  177. Lyte M, Daniels KM, Schmitz-Esser S. Fluoxetine-induced alteration of murine gut microbial community structure: evidence for a microbial endocrinology-based mechanism of action responsible for fluoxetine-induced side effects. PeerJ 2019; 7:e6199 [View Article] [PubMed]
     [Google Scholar]
  178. Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE et al. Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. Cell Host Microbe 2016; 19:455–469 [View Article] [PubMed]
     [Google Scholar]
  179. Zheng S, Shao S, Qiao Z, Chen X, Piao C et al. Clinical parameters and gut microbiome changes before and after surgery in thoracic aortic dissection in patients with gastrointestinal complications. Sci Rep 2017; 7:15228 [View Article]
     [Google Scholar]
  180. Song Y, Könönen E, Rautio M, Liu C, Bryk A et al. Alistipes onderdonkii sp. nov. and Alistipes shahii sp. nov., of human origin. Int J Syst Evol Microbiol 2006; 56:1985–1990 [View Article] [PubMed]
     [Google Scholar]
  181. Walsh J, Griffin BT, Clarke G, Hyland NP. Drug-gut microbiota interactions: implications for neuropharmacology. Br J Pharmacol 2018; 175:4415–4429 [View Article] [PubMed]
     [Google Scholar]
  182. Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One 2018; 13:e0204941 [View Article] [PubMed]
     [Google Scholar]
  183. Laugisch O, Johnen A, Maldonado A, Ehmke B, Bürgin W et al. Periodontal pathogens and associated intrathecal antibodies in early stages of alzheimer’s disease. J Alzheimers Dis 2018; 66:105–114 [View Article] [PubMed]
     [Google Scholar]
  184. Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A et al. GABA-modulating bacteria of the human gut microbiota. Nat Microbiol 2019; 4:396–403 [View Article] [PubMed]
     [Google Scholar]
  185. Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 2011; 16:383–406 [View Article] [PubMed]
     [Google Scholar]
  186. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 2016; 7:12015 [View Article] [PubMed]
     [Google Scholar]
  187. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27:104–119 [View Article] [PubMed]
     [Google Scholar]
  188. Zhang L, Huang Y, Zhou Y, Buckley T, Wang HH. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob Agents Chemother 2013; 57:3659–3666 [View Article] [PubMed]
     [Google Scholar]
  189. Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M et al. Oral ketamine for depression: a systematic review. J Clin Psychiatry 2019; 80:18r12475 [View Article] [PubMed]
     [Google Scholar]
  190. Zheng W, Cai D-B, Xiang Y-Q, Zheng W, Jiang W-L et al. Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 2020; 265:63–70 [View Article] [PubMed]
     [Google Scholar]
  191. Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry 2020; 54:29–45 [View Article] [PubMed]
     [Google Scholar]
  192. McIntyre RS, Lipsitz O, Rodrigues NB, Lee Y, Cha DS et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord 2020; 22:831–840 [View Article] [PubMed]
     [Google Scholar]
  193. Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW et al. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. Neuroimage Clin 2018; 20:92–101 [View Article] [PubMed]
     [Google Scholar]
  194. Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res 2018; 7:F1000 Faculty Rev-659 [View Article] [PubMed]
     [Google Scholar]
  195. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22:238–249 [View Article] [PubMed]
     [Google Scholar]
  196. Pałucha-Poniewiera A. The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug. Pharmacol Rep 2018; 70:837–846 [View Article] [PubMed]
     [Google Scholar]
  197. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper t cell responses. Immunity 2009; 31:677–689 [View Article] [PubMed]
     [Google Scholar]
  198. Hansen SGK, Skov MN, Justesen US. Two cases of Ruminococcus gnavus bacteremia associated with diverticulitis. J Clin Microbiol 2013; 51:1334–1336 [View Article] [PubMed]
     [Google Scholar]
  199. Lennon P, Saunders J, Fenton JE. A longer stay for the kissing disease: epidemiology of bacterial tonsillitis and infectious mononucleosis over a 20-year period. J Laryngol Otol 2013; 127:187–191
     [Google Scholar]
  200. Moreno-Indias I, Torres M, Sanchez-Alcoholado L, Cardona F, Almendros I et al. Normoxic recovery mimicking treatment of sleep apnea does not reverse intermittent hypoxia-induced bacterial dysbiosis and low-grade endotoxemia in mice. Sleep 2016; 39:1891–1897
     [Google Scholar]
  201. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol 2007; 56:165–171 [View Article] [PubMed]
     [Google Scholar]
  202. Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J 2014; 8:1403–1417 [View Article] [PubMed]
     [Google Scholar]
  203. Robertson BR, O’Rourke JL, Neilan BA, Vandamme P, On SLW et al. Mucispirillum schaedleri gen. nov., sp. nov., a spiral-shaped bacterium colonizing the mucus layer of the gastrointestinal tract of laboratory rodents. Int J Syst Evol Microbiol 2005; 55:1199–1204 [View Article] [PubMed]
     [Google Scholar]
  204. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG et al. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. Brain, Behavior, and Immunity 2011; 25:397–407 [View Article]
     [Google Scholar]
  205. Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K et al. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J 2012; 6:2091–2106 [View Article] [PubMed]
     [Google Scholar]
  206. Qu Y, Yang C, Ren Q, Ma M, Dong C et al. Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model. Sci Rep 2017; 7:15725 [View Article]
     [Google Scholar]
  207. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108:16050–16055 [View Article] [PubMed]
     [Google Scholar]
  208. Zhong Y, Nyman M, Fåk F. Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt. Mol Nutr Food Res 2015; 59:2066–2076 [View Article] [PubMed]
     [Google Scholar]
  209. Kunugi H. Depressive disorder and gut-brain interaction. Brain Nerve 2016; 68:641–646 [View Article] [PubMed]
     [Google Scholar]
  210. Rossi G, Pengo G, Caldin M, Palumbo Piccionello A, Steiner JM et al. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS One 2014; 9:e94699 [View Article] [PubMed]
     [Google Scholar]
  211. Getachew B, Aubee JI, Schottenfeld RS, Csoka AB, Thompson KM et al. Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties. BMC Microbiol 2018; 18:222 [View Article] [PubMed]
     [Google Scholar]
  212. Turner PV. The role of the gut microbiota on animal model reproducibility. Anim Models and Exp Med 2018; 1:109–115 [View Article]
     [Google Scholar]
  213. Toutain PL, Ferran A, Bousquet-Mélou A. Species differences in pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol 201019–48 [View Article] [PubMed]
     [Google Scholar]
  214. Fiebiger U, Bereswill S, Heimesaat MM. Dissecting the interplay between intestinal microbiota and host immunity in health and disease: lessons learned from germfree and gnotobiotic animal models. EuJMI 2016; 6:253–271 [View Article]
     [Google Scholar]
  215. Wos-Oxley M, Bleich A, Oxley APA, Kahl S, Janus LM et al. Comparative evaluation of establishing a human gut microbial community within rodent models. Gut Microbes 2012; 3:234–249 [View Article] [PubMed]
     [Google Scholar]
  216. Edwards M, Dai R, Ahmed SA. Our environment shapes us: the importance of environment and sex differences in regulation of autoantibody production. Front Immunol 2018; 9:478 [View Article] [PubMed]
     [Google Scholar]
  217. Cross TWL, Kasahara K, Rey FE. Sexual dimorphism of cardiometabolic dysfunction: gut microbiome in the play?. Mol Metab 2018; 15:70–81 [View Article] [PubMed]
     [Google Scholar]
  218. Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P et al. Intestinal microbiota is influenced by gender and body mass index. PLoS One 2016; 11:e0154090 [View Article] [PubMed]
     [Google Scholar]
  219. Teatero ML, Mazmanian D, Sharma V. Effects of the menstrual cycle on bipolar disorder. Bipolar Disord 2014; 16:22–36 [View Article] [PubMed]
     [Google Scholar]
  220. El Dahr Y, de Azevedo Cardoso T, Syan SK, Caropreso L, Minuzzi L et al. Investigating biological rhythms disruptions across the menstrual cycle in women with comorbid bipolar disorder and premenstrual dysphoric disorder. Arch Womens Ment Health 2022; 25:345–353 [View Article] [PubMed]
     [Google Scholar]
  221. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48:143–157 [View Article] [PubMed]
     [Google Scholar]
  222. Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol 2015; 13:386–397 [View Article] [PubMed]
     [Google Scholar]
  223. Feldman M, Barnett C. Fasting gastric pH and its relationship to true hypochlorhydria in humans. Dig Dis Sci 1991; 36:866–869 [View Article] [PubMed]
     [Google Scholar]
  224. Rao SSC, Kuo B, McCallum RW, Chey WD, DiBaise JK et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clinical Gastroenterology and Hepatology 2009; 7:537–544 [View Article]
     [Google Scholar]
  225. Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M. Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol 2014; 20:10331–10337 [View Article] [PubMed]
     [Google Scholar]
  226. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 2019; 570:462–467
     [Google Scholar]
  227. Bennink R, Peeters M, Van den Maegdenbergh V, Geypens B, Rutgeerts P et al. Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med 1998; 25:1293–1299 [View Article] [PubMed]
     [Google Scholar]
  228. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017; 13:2231–2241 [View Article] [PubMed]
     [Google Scholar]
  229. McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic Drug–Related Weight Gain and Its Treatment. AJP 2024; 181:26–38 [View Article]
     [Google Scholar]
  230. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61:1356–1370 [View Article] [PubMed]
     [Google Scholar]
  231. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90:1236–1243 [View Article] [PubMed]
     [Google Scholar]
  232. van de Wouw M, Schellekens H, Dinan TG, Cryan JF. Microbiota-gut-brain axis: modulator of host metabolism and appetite. J Nutr 2017; 147:727–745 [View Article] [PubMed]
     [Google Scholar]
  233. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ 2018; 361:k1951 [View Article] [PubMed]
     [Google Scholar]
  234. Kastl AJ, Terry NA, Wu GD, Albenberg LG. The structure and function of the human small intestinal microbiota: current understanding and future directions. Cell Mol Gastroenterol Hepatol 2020; 9:33–45 [View Article] [PubMed]
     [Google Scholar]
  235. Wang Z, Li H, Kang Y, Liu Y, Shan L et al. Risks of digestive system side-effects of selective serotonin reuptake inhibitors in patients with depression: a network meta-analysis. Ther Clin Risk Manag 2022; 18:799–812 [View Article] [PubMed]
     [Google Scholar]
  236. Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013; 10:473–486 [View Article] [PubMed]
     [Google Scholar]
  237. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010; 127210–251 [View Article] [PubMed]
     [Google Scholar]
  238. Giskes K, van Lenthe F, Avendano‐Pabon M, Brug J. A systematic review of environmental factors and obesogenic dietary intakes among adults: are we getting closer to understanding obesogenic environments?. Obesity Reviews 2011; 12:e95–106 [View Article]
     [Google Scholar]
  239. Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M et al. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology 2016; 233:2629–2653 [View Article] [PubMed]
     [Google Scholar]
  240. Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry 2014; 59:76–88 [View Article]
     [Google Scholar]
  241. Cederlund H, Mårdh PA. Antibacterial activities of non-antibiotic drugs. J Antimicrob Chemother 1993; 32:355–365 [View Article]
     [Google Scholar]
  242. Caldara M, Marmiroli N. Antimicrobial properties of antidepressants and antipsychotics-possibilities and implications. Pharmaceuticals 202119 October 2023 14:915 [View Article] [PubMed]
     [Google Scholar]
  243. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 2009; 108:127–133 [View Article] [PubMed]
     [Google Scholar]
  244. Rukavishnikov G, Leonova L, Kasyanov E, Leonov V, Neznanov N et al. Antimicrobial activity of antidepressants on normal gut microbiota: Results of the in vitro study. Front Behav Neurosci 2023; 17:1132127 [View Article]
     [Google Scholar]
  245. Nehme H, Saulnier P, Ramadan AA, Cassisa V, Guillet C et al. Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity. PLoS One 2018; 13:e0189950 [View Article] [PubMed]
     [Google Scholar]
  246. Chaves Filho AJM, Mottin M, Soares MVR, Jucá PM, Andrade CH et al. Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. Behav Pharmacol 2021; 32:123–141 [View Article] [PubMed]
     [Google Scholar]
  247. Murrough JW, Huryk KM, Mao X, Iacoviello B, Collins K et al. A pilot study of minocycline for the treatment of bipolar depression: effects on cortical glutathione and oxidative stress in vivo. J Affect Disord 2018; 230:56–64 [View Article] [PubMed]
     [Google Scholar]
  248. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 2012; 235:302–317 [View Article] [PubMed]
     [Google Scholar]
  249. Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry 2018; 8:27 [View Article] [PubMed]
     [Google Scholar]
  250. Upmark F, Sjöqvist H, Hayes JF, Dalman C, Karlsson H. Doxycycline exposure during adolescence and future risk of non-affective psychosis and bipolar disorder: a total population cohort study. Transl Psychiatry 2021; 11:468 [View Article] [PubMed]
     [Google Scholar]
  251. Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry 2020; 7:515–527 [View Article] [PubMed]
     [Google Scholar]
  252. Li XM, Shi ZM, Wang PJ, Hu H. Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials. Gen Psychiatr 2020; 33:e100117 [View Article] [PubMed]
     [Google Scholar]
  253. Macedo D, Filho AJMC, Soares de Sousa CN, Quevedo J, Barichello T et al. Antidepressants, antimicrobials or both? gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Disord 2017; 208:22–32 [View Article] [PubMed]
     [Google Scholar]
  254. Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 2016; 22:178 [View Article] [PubMed]
     [Google Scholar]
  255. Ohlsson L, Gustafsson A, Lavant E, Suneson K, Brundin L et al. Leaky gut biomarkers in depression and suicidal behavior. Acta Psychiatr Scand 2019; 139:185–193 [View Article] [PubMed]
     [Google Scholar]
  256. Papadimitriou GN, Dikeos DG, Soldatos CR, Calabrese JR. Non-pharmacological treatments in the management of rapid cycling bipolar disorder. J Affect Disord 2007; 98:1–10 [View Article] [PubMed]
     [Google Scholar]
  257. Geller B, Tillman R, Bolhofner K, Zimerman B. Pharmacological and non‐drug treatment of child bipolar I disorder during prospective eight‐year follow‐up. Bipolar Disorders 2010; 12:164–171 [View Article]
     [Google Scholar]
  258. Kerimi A, Kraut NU, da Encarnacao JA, Williamson G. The gut microbiome drives inter- and intra-individual differences in metabolism of bioactive small molecules. Sci Rep 2020; 10:19590 [View Article] [PubMed]
     [Google Scholar]
  259. Healey GR, Murphy R, Brough L, Butts CA, Coad J. Interindividual variability in gut microbiota and host response to dietary interventions. Nutr Rev 2017; 75:1059–1080 [View Article]
     [Google Scholar]
  260. Kelly JR, Borre Y, O’ Brien C, Patterson E, El Aidy S et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res 2016; 82:109–118 [View Article] [PubMed]
     [Google Scholar]
  261. Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil 2014; 26:1155–1162 [View Article]
     [Google Scholar]
  262. Firth J, Marx W, Dash S, Carney R, Teasdale SB et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med 2019; 81:265–280 [View Article]
     [Google Scholar]
  263. Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S et al. A randomised controlled trial of dietary improvement for adults with major depression (the “SMILES” trial). BMC Med 2017; 15:23 [View Article] [PubMed]
     [Google Scholar]
  264. Eltokhi A, Janmaat IE, Genedi M, Haarman BCM, Sommer IEC. Dysregulation of synaptic pruning as a possible link between intestinal microbiota dysbiosis and neuropsychiatric disorders. J Neurosci Res 2020; 98:1335–1369 [View Article]
     [Google Scholar]
  265. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G et al. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015; 9:392 [View Article]
     [Google Scholar]
  266. Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health?. Neurosci Lett 2016; 625:56–63 [View Article] [PubMed]
     [Google Scholar]
  267. Deng J, Zhu X, Chen Z, Fan CH, Kwan HS et al. A Review of food-drug interactions on oral drug absorption. Drugs 2017; 77:1833–1855 [View Article] [PubMed]
     [Google Scholar]
  268. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The mediterranean diet, its components, and cardiovascular disease. Am J Med 2015; 128:229–238 [View Article] [PubMed]
     [Google Scholar]
  269. Meslier V, Laiola M, Roager HM, De Filippis F, Roume H et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut 2020; 69:1258–1268 [View Article] [PubMed]
     [Google Scholar]
  270. Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG et al. Influence of mediterranean diet on human gut microbiota. Nutrients 2020; 13:7 [View Article] [PubMed]
     [Google Scholar]
  271. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients 2013; 5:1417–1435 [View Article]
     [Google Scholar]
  272. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K et al. Health benefits of probiotics: a review. ISRN Nutr 2013; 2013:481651 [View Article] [PubMed]
     [Google Scholar]
  273. Dickerson F, Adamos M, Katsafanas E, Khushalani S, Origoni A et al. Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: a randomized controlled trial. Bipolar Disord 2018; 20:614–621 [View Article] [PubMed]
     [Google Scholar]
  274. Reininghaus EZ, Wetzlmair L-C, Fellendorf FT, Platzer M, Queissner R et al. The impact of probiotic supplements on cognitive parameters in euthymic individuals with bipolar disorder: a pilot study. Neuropsychobiology 2020; 79:63–70 [View Article]
     [Google Scholar]
  275. Vindigni SM, Surawicz CM. Fecal microbiota transplantation. Gastroenterol Clin North Am 2017; 46:171–185 [View Article] [PubMed]
     [Google Scholar]
  276. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 2016; 9:229–239 [View Article]
     [Google Scholar]
  277. Hinton R. A case report looking at the effects of faecal microbiota transplantation in a patient with bipolar disorder. Aust N Z J Psychiatry 2020; 54:649–650 [View Article] [PubMed]
     [Google Scholar]
  278. Zhang P, Kong L, Huang H, Pan Y, Zhang D et al. Gut Microbiota - a potential contributor in the pathogenesis of bipolar disorder. Front Neurosci 202221 September 2023 16:830748 [View Article] [PubMed]
     [Google Scholar]
  279. Colpo GD, Leboyer M, Dantzer R, Trivedi MH, Teixeira AL. Immune-based strategies for mood disorders: facts and challenges. Expert Rev Neurother 2018; 18:139–152 [View Article] [PubMed]
     [Google Scholar]
  280. Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord 2020; 261:145–152 [View Article] [PubMed]
     [Google Scholar]
  281. Rapoport SI. Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder. Med Hypotheses 2021; 149:110536 [View Article] [PubMed]
     [Google Scholar]
  282. Zheng J, Yuan X, Zhang C, Jia P, Jiao S et al. N ‐Acetylcysteine alleviates gut dysbiosis and glucose metabolic disorder in high‐fat diet‐fed mice. J Diabetes 2019; 11:32–45 [View Article] [PubMed]
     [Google Scholar]
  283. Berk M, Copolov DL, Dean O, Lu K, Jeavons S et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biological Psychiatry 2008; 64:468–475 [View Article]
     [Google Scholar]
/content/journal/micro/10.1099/mic.0.001568
Loading
Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder
Microbiology 171, 001568 (2025); https://doi.org/10.1099/mic.0.001568
/content/journal/micro/10.1099/mic.0.001568
/content/journal/micro/10.1099/mic.0.001568
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error